91九色视频

header-logo
Research Collaborate Lab Hall
headshot

Nirav N. Shah, MD

Professor; Clinical Director, BMT and Cellular Therapy

view physician profile

Locations

  • Froedtert Hospital
  • Clinical Cancer Center - Froedtert Hospital

Specialties

  • Hematology
  • Medical Oncology

Languages

  • English, Gujarati

Clinical Cancer Center - Froedtert Hospital

Education

  • MD - Doctor of Medicine

Biography

Nirav Shah, MD, MSHP, is Assistant Professor of Medicine at the 91九色视频, Division of Hematology and Oncology, specializing in lymphoma, CAR-T cell therapy, and stem cell transplant at Froedtert Hospital. He graduated with honors and Alpha Omega Alpha Honor Society membership from the University of Illinois at Chicago College of Medicine in 2008. He then completed his Internal Medicine residency at Massachusetts General Hospital in Boston, Massachusetts in 2011. Post-residency, he took a position at Northwestern Memorial Hospital in Hospitalist medicine before proceeding to the University of Pennsylvania where he completed both hematology/oncology fellowship and a Master’s degree in Health Policy research in 2015.

Research Interests

Dr. Shah's current clinical and research interests include developing new cell based and immune therapies for patients with non-Hodgkin and Hodgkin lymphoma. He is specifically involved in the development of new CAR-T cell therapies for blood cancers. His professional memberships include the American Society of Hematology and the American Society of Clinical Oncology.

Dr. Shah is board certified by the American Board of Internal Medicine (ABIM) in Hematology, Medical Oncology, and Internal Medicine.

Publications

  • (Hines MR, Knight TE, McNerney KO, Leick MB, Jain T, Ahmed S, Frigault MJ, Hill JA, Jain MD, Johnson WT, Lin Y, Mahadeo KM, Maron GM, Marsh RA, Neelapu SS, Nikiforow S, Ombrello AK, Shah NN, Talleur AC, Turicek D, Vatsayan A, Wong SW, Maus MV, Komanduri KV, Berliner N, Henter JI, Perales MA, Frey NV, Teachey DT, Frank MJ, Shah NN.) Transplant Cell Ther. 2025 Oct 30 PMID: 41067707 10/10/2025

  • (Brown JR, Nguyen B, Desikan SP, Won H, Tantawy SI, McNeely SC, Marella N, Randeria HS, Hanson LM, Parker A, Calado Botelho S, Woyach JA, Patel K, Tam CS, Eyre TA, Cheah CY, Shah NN, Ghia P, Jurczak W, Balbas M, Nair BC, Abada PB, Wang C, Wang D, Roeker LE, Gandhi V, Wierda WG.) Blood. 2025 Oct 07 PMID: 41055698 10/07/2025

  • (Shah NN, Zinzani PL, Wang ML, Nasta SD, Lech-Maranda E, Ogawa Y, Fakhri B, Kuss BJ, Miyashita K, Patel K, Coombs CC, Ma S, Patel MR, Barve M, Tessoulin B, Stathis A, Ennishi D, Hashimoto D, Kojima K, Zelenetz AD, Cohen JB, Vose JM, Maddocks KJ, Munir T, Sun F, Bian Y, Balbas M, Tsai DE, Abada PB, Cheah CY.) Blood Adv. 2025 Aug 22 PMID: 40845254 08/22/2025

  • (Nadiminti KV, Ahn KW, Patel J, Lian Q, Bezerra E, Chen A, Ganguly S, Gergis U, Hashmi H, Kharfan-Dabaja MA, Kuruvilla J, Lekakis L, Locke FL, Murthy H, Mousthafa MA, Perales MA, Pophali P, Riedell PA, Shah NN, Wang T, Pasquini M, Hamadani M, Turtle CJ, Herrera AF, Shadman M.) Transplant Cell Ther. 2025 Aug 05 PMID: 40754223 SCOPUS ID: 2-s2.0-105019071503 08/04/2025

  • (Frigault MJ, Maziarz RT, Park JH, Lazaryan A, Shah NN, Svoboda J, Lekakis L, Reshef R, Phillips CL, Burke L, Lei J, Pratta M, Morariu-Zamfir R, DiPersio JF.) Blood. 2025 Jul 24;146(4):422-436 PMID: 40090005 SCOPUS ID: 2-s2.0-105008544409 03/16/2025

  • (Shah NN, Colina AS, Johnson BD, Szabo A, Furqan F, Kearl T, Schneider D, Vargas-Cortes M, Schmeling JL, Dwinell MB, Palen K, Longo W, Hematti P, Zamora AE, Hari P, Bucklan D, Cunningham A, Hamadani M, Fenske TS.) J Clin Oncol. 2025 Jul 10;43(20):2285-2295 PMID: 40163793 SCOPUS ID: 2-s2.0-105010720202 03/31/2025

  • (Kwiatek M, Murthy GSG, Hoffmann M, Tessoulin B, Danilov A, Alencar AJ, Shah NN, Ghesquieres H, Le Gouill S, Jurczak W, Han H, Yuen E, Patel V, Guo-Avrutin Y, Pauff JM, Roeker LE.) Clin Lymphoma Myeloma Leuk. 2025 Jul;25(7):512-519 PMID: 40000354 SCOPUS ID: 2-s2.0-85218857552 02/26/2025

  • (Karmali R, Shouse G, Torka P, Moyo TK, Romancik J, Barta SK, Bhansali R, Cohen JB, Shah NN, Zurko J, Kenkre VP, Hess B, Stephens DM, Fitzgerald L, Ollila T, Tabiti B, Roy I, Ma S, Winter J, Pro B, Moreira J, Danilov AV, David K, Gordon LI, Epperla N.) Blood Cancer J. 2025 Mar 26;15(1):43 PMID: 40140360 PMCID: PMC11947441 SCOPUS ID: 2-s2.0-105000866957 03/27/2025

  • (Kwiatek M, Murthy GSG, Hoffmann M, Tessoulin B, Danilov A, Alencar AJ, Shah NN, Ghesquieres H, Le Gouill S, Jurczak W, Han H, Yuen E, Patel V, Guo-Avrutin Y, Pauff JM, Roeker LE.) Clinical Lymphoma Myeloma and Leukemia. July 2025;25(7):512-519 SCOPUS ID: 2-s2.0-85218857552 07/01/2025

  • (Shah NN, Wang M, Roeker LE, Patel K, Woyach JA, Wierda WG, Ujjani CS, Eyre TA, Zinzani PL, Alencar AJ, Ghia P, Lamanna N, Hoffmann MS, Patel MR, Flinn I, Gerson JN, Ma S, Coombs CC, Cheah CY, Lech-Maranda E, Fakhri B, Kim WS, Barve MA, Cohen JB, Jurczak W, Munir T, Thompson MC, Tsai DE, Bao K, Cangemi NA, Kherani JF, Walgren RA, Han H, Ruppert AS, Brown JR.) Haematologica. 2025 Jan 01;110(1):92-102 PMID: 39363864 PMCID: PMC11694105 SCOPUS ID: 2-s2.0-85214310390 10/04/2024

  • (Kearl TJ, Furqan F, Shah NN.) Cancer Metastasis Rev. 2024 Dec 01;44(1):12 PMID: 39617795 SCOPUS ID: 2-s2.0-85211169496 12/02/2024

  • (Akhtar OS, Arshad S, Lian Q, Ahn KW, D'Souza A, Dhakal B, Mohan M, Pasquini M, Longo W, Shah NN, Fenske TS, Hamadani M.) Transplant Cell Ther. 2024 Dec;30(12):1191.e1-1191.e8 PMID: 39303985 PMCID: PMC12483827 SCOPUS ID: 2-s2.0-85206435293 09/21/2024

Publications of from the

© 2025 91九色视频.  All rights reserved.  | Terms and Privacy | Web Accessibility Statement

Non-Discrimination, Anti-Harassment, and Legal Compliance Statement
The 91九色视频 (91九色视频) is committed to fostering a diverse community of outstanding faculty, staff, and students, as well as ensuring equal educational opportunity, employment, and access to services, programs, and activities, without regard to an individual's race, color, national origin, religion, age, disability, sex, gender identity/expression, sexual orientation, marital status, pregnancy, predisposing genetic characteristic, military status, or other legally protected classification. 91九色视频 maintains full compliance with all applicable federal, state, and local laws and regulations in pursuit of our missions. Consistent with federal guidance, we affirm our commitment to individual merit, fairness, and equal treatment in all aspects of academic and institutional decision-making.

91九色视频's policies, federal and state laws, and regulations prohibit unlawful discrimination and harassment. Employees, learners, students, applicants, or other members of the 91九色视频 community (including but not limited to vendors, visitors, and guests) may not be subjected to harassment that is prohibited by law or treated adversely or retaliated against based upon a protected characteristic.